Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations

被引:17
作者
Xu, Dan [1 ,2 ,3 ]
Nair, Ankith [2 ]
Sigston, Charlie [4 ]
Ho, Chau [1 ]
Li, Jia [5 ]
Yang, Daya [3 ,6 ]
Liao, Xinxue [3 ,6 ]
Chen, Wei [3 ,7 ]
Kuang, Ming [3 ,8 ]
Li, Yanbing [3 ,9 ]
Reid, Christopher [1 ]
Xiao, Haipeng [3 ,9 ]
机构
[1] Curtin Univ, Fac Hlth Sci, Curtin Sch Populat Hlth, CCRE, Bentley, WA, Australia
[2] Curtin Univ, Fac Hlth Sci, Curtin Med Sch, Bentley, WA, Australia
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Med Educ, Guangzhou, Peoples R China
[4] St John God Midland Publ & Private Hosp, 1 Clayton St, Midland, WA 6056, Australia
[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pharm, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Renal Med, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Surg, Guangzhou, Peoples R China
[9] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Peoples R China
关键词
LEFT-VENTRICULAR FUNCTION; METFORMIN-TREATED PATIENTS; CARDIOVASCULAR OUTCOMES; DOUBLE-BLIND; ACUTE-PANCREATITIS; GLYCEMIC CONTROL; CONTROLLED-TRIAL; HEART-FAILURE; WEIGHT-LOSS; OPEN-LABEL;
D O I
10.1155/2022/6820377
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been observed in several large cardiovascular outcome trials to significantly reduce the incidence of major cardiovascular event (MACE) with type 2 diabetic patients. The clinical trials of GLP-1 RAs, including lixisenatide, exenatide, liraglutide, semaglutide, albiglutide, and dulaglutide, are associated with a significantly 14% lower risk of MACE in patients with T2DM and a history of CV disease, and with a nonsignificantly 6% lower risk in patients without history of CV disease. Some of the interpretation with GLP-1 RA trials suggested the possible role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in primary prevention of cardiovascular diseases in nondiabetic individual, echoed by a recent editorial redefining the role of GLP-1 RAs being beyond glycaemic control. The narrative review provides an in-depth insight into GLP-1 RA use guideline in different countries and regions of the world and examines the safety and concern of GLP-1 RA use. The narrative review draws the comparison of GLP-1 RA use between diabetic and nondiabetic individual in terms of cardiovascular and metabolic benefits and points out the direction of future clinical trials of GLP-1 RAs in nondiabetic individuals. The focus of the review is on GLP-1 RAs' preventive roles in nondiabetic individuals with cardiovascular disease, chronic kidney diseases, obesity, dyslipidaemia, hypertension, nonalcoholic fatty liver diseases, polycystic ovarian syndrome (PCOS), and perioperative complications of bariatric surgery, albeit in small studies and subset analysis of clinical trials of diabetic patients.
引用
收藏
页数:9
相关论文
共 78 条
  • [1] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022
    American Diabetes Association Professional Practice Committee
    [J]. DIABETES CARE, 2022, 45 : S125 - S143
  • [3] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong, Matthew James
    Gaunt, Piers
    Aithal, Guruprasad P.
    Barton, Darren
    Hull, Diana
    Parker, Richard
    Hazlehurst, Jonathan M.
    Guo, Kathy
    Abouda, George
    Aldersley, Mark A.
    Stocken, Deborah
    Gough, Stephen C.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    [J]. LANCET, 2016, 387 (10019) : 679 - 690
  • [4] Australian Medicine Handbook (AMH), 2022, GLUC LIK PEPT AN
  • [5] Biology of incretins: GLP-1 and GIP
    Baggio, Laurie L.
    Drucker, Daniel J.
    [J]. GASTROENTEROLOGY, 2007, 132 (06) : 2131 - 2157
  • [6] Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions
    Beti, Christelle
    Stratmann, Bernd
    Bokman, Georgy
    Dreier, Jens
    Hauber, Michael
    Lee-Barkey, Young Hee
    Fischer, Manfred
    Knabbe, Cornelius
    Tschoepe, Diethelm
    [J]. HORMONE AND METABOLIC RESEARCH, 2019, 51 (04) : 267 - 273
  • [7] Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    Buse, John B.
    Klonoff, David C.
    Nielsen, Loretta L.
    Guan, Xuesong
    Bowlus, Christopher L.
    Holcombe, John H.
    Maggs, David G.
    Wintle, Matthew E.
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (01) : 139 - 153
  • [8] Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Chen, Wei Ren
    Hu, Shun Ying
    Chen, Yun Dai
    Zhang, Ying
    Qian, Geng
    Wang, Jing
    Yang, Jun Jie
    Wang, Zhi Feng
    Tian, Feng
    Ning, Qing Xiu
    [J]. AMERICAN HEART JOURNAL, 2015, 170 (05) : 845 - 854
  • [9] Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction
    Chen, Wei-Ren
    Shen, Xue-Qin
    Zhang, Ying
    Chen, Yun-Dai
    Hu, Shun-Ying
    Qian, Geng
    Wang, Jing
    Yang, Jun-Jie
    Wang, Zhi-Feng
    Tian, Feng
    [J]. ENDOCRINE, 2016, 52 (03) : 516 - 526
  • [10] Chinese Society of Endocrinology, 2020, Zhonghua Nei Ke Za Zhi, V59, P836, DOI 10.3760/cma.j.cn112138-20200704-00646